Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.87 USD
+0.02 (1.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.87 0.00 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.87 USD
+0.02 (1.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.87 0.00 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
Monkeypox Fears Drive Smallpox Antiviral Makers Higher
by Kinjel Shah
Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates
by Zacks Equity Research
The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.
Chimerix (CMRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of -309.09% and 99.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of -14.52% and 2.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Chimerix (CMRX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and -72.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Chimerix (CMRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon
Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.
Company News for Jan 11, 2021
by Zacks Equity Research
Companies in the news are: CMRX, GSAT, MRUS, FFIV
Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA
by Zacks Equity Research
Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Chimerix (CMRX) Rating Upgrade to Buy
by Zacks Equity Research
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CMRX) Outperforming Other Medical Stocks This Year?
Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Chimerix to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Chimerix.
Chimerix (CMRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Chimerix (CMRX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
by Zacks Equity Research
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
by Zacks Equity Research
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.